00:16:51 · Robin Guo
[00:16:51] S0: Oh, I mean, was a I was a a16z, consumer a16z for five years. So I I took a break for a bit. Yeah. I... So I I loved two things in my... Okay. I loved three things in my life. It was like science, robotics, and like video games. Mhmm. And so basically my entire career has been dedicated to those things. It's like I studied biomedical engineering and then I did some pharma stuff and then really didn't like it actually because old school pharma, it's very slow. And so it like literally takes ten years to get a drug to market. Right? And there's no reason it should take ten years. Obviously we need to do tests and tests do take some time. But the clinical trial program is fully constructed by humans, right? And this is how we decided that drugs should be approved. And so I laughed and then I came to Valley, probably similar to yourself to like work on cool tech stuff, which moves much faster. But I think I was always interested in science because I think in many ways, I mean, I'm sure other people agree, like it's kind of the final frontier of like, well, space might be the final frontier, but I think in another way, bio is also the final frontier of like, how can we live longer? How can we be healthier? How can we cure Alzheimer's? How can we cure? And so I think for me starting this company, the main goal was very personal, is we work on like neuropeptides, right? Things that can go to the brain. And I have like two grandparents with Alzheimer's right now in the ward. And so that's kind of the long term goal is like, Hey, look, there's a reasonable chance my parents get Alzheimer's. There's a reasonable chance that I get Alzheimer's. I wanna make sure that we are able to deliver whatever therapeutics in the future can make us ourselves for longer, right? Because I think Alzheimer's is probably one of the worst diseases because you not only, the other diseases you pass away, but then Alzheimer's you basically like see someone slowly lose themselves and like slowly become someone that you don't know and like forget you and then basically can't walk and then all these, and then they can't swallow and all these things. So it's a very sad process basically.
00:18:52 · Ruby Justice Thelot, Robin Guo
[00:18:52] S1: Yeah. I also have a grandma who has Alzheimer's. I'm sorry to hear that about your Do grandparents as you think there'll be some preventative solution for our parents by the time that they might develop Alzheimer's? [00:19:06] S0: I think so. I think it's a combination of all the people working on interesting BCI tech plus AI. AI is very good at targeting right now. So all the protein folding models, all the omics models, they're very good at figuring out like, hey, this disease state has these things. This protein confirmation has these things, or this bacteria has these things. What are different targets that we can try? So I think we'll be able to figure it out within the next like decade hopefully. And then the matter is trying to get the therapy into the brain to actually target it, right? And so that's kind of what we're working on. It's like, hey, someone needs to develop the therapy and then you need to deliver it to the right area, right? Because it doesn't matter if you have cancer, you need to make sure it's directed at the tumor, right? You can't just throw the cancer drug all across your body because then it'll have a bunch of deleterious effects and cause a bunch of toxicity.
00:19:06 · Robin Guo, Ruby Justice Thelot
[00:19:06] S0: I think so. I think it's a combination of all the people working on interesting BCI tech plus AI. AI is very good at targeting right now. So all the protein folding models, all the omics models, they're very good at figuring out like, hey, this disease state has these things. This protein confirmation has these things, or this bacteria has these things. What are different targets that we can try? So I think we'll be able to figure it out within the next like decade hopefully. And then the matter is trying to get the therapy into the brain to actually target it, right? And so that's kind of what we're working on. It's like, hey, someone needs to develop the therapy and then you need to deliver it to the right area, right? Because it doesn't matter if you have cancer, you need to make sure it's directed at the tumor, right? You can't just throw the cancer drug all across your body because then it'll have a bunch of deleterious effects and cause a bunch of toxicity. [00:19:58] S1: Super fascinating, Robin. Really wanted to thank you for joining us today on MTS and also getting your perspective on some of the timelines here. As you mentioned AI when it comes to BCIs biotech consumer health, delivering straight to the brain and being able to target the drugs directly where they need to go is uniquely possible with the technology that exists today. So really wanted to thank you for joining us, sharing more about LionBio and all the updates. Thank you for joining. Yeah. A huge thanks to MTS sponsors.
00:19:58 · Ruby Justice Thelot, S2
[00:19:58] S1: Super fascinating, Robin. Really wanted to thank you for joining us today on MTS and also getting your perspective on some of the timelines here. As you mentioned AI when it comes to BCIs biotech consumer health, delivering straight to the brain and being able to target the drugs directly where they need to go is uniquely possible with the technology that exists today. So really wanted to thank you for joining us, sharing more about LionBio and all the updates. Thank you for joining. Yeah. A huge thanks to MTS sponsors. Ad[00:20:26] S2: ElevenLabs, AI that communicates at human level across every channel and modality. Elevenlabs.io/mts. Scale your startup on Neon. Millions of developers and startups have already chosen Neon for their back end. Start on the free plan or get up to a $100,000 in credits for your startup at neon.com/mts. Special thanks to our sponsor, Kong, the AI connectivity platform. Connect APIs, LLMs, agents, and systems with serious security and governance. Konghq.com.
00:20:56 · Ruby Justice Thelot
[00:20:56] S1: Finally, prove what your AI investment is worth with Larridin. Head to lairdon.com today to start measuring your AI's bottom line. MongoDB, trusted to run critical applications by 75% of the Fortune one hundred, the intelligent data platform for the era. Apply today for access to up to $15,000 in Atlas credits, dedicated technical support, and exclusive events and go to market opportunities. Mongodb.com. Chargebee, billing and monetization infrastructure for the AI era. Chargebee.com. Blitzy, autonomous software development for enterprise code bases. Ship five x faster. Blitzy.com. Adquick, make your brand a billboard out of home advertising as easy to scale as digital. Adquick.com. Arena, measuring AI performance in the real world. Arena.ai. Support for the show comes from VCX, the public ticker for private tech. The US stock market started history's greatest wave of wealth creation. From factory workers in Detroit to farmers in Omaha, anyone could own a piece of the great American companies. But today, our most innovative companies are staying private longer, which means everyday Americans are missing out. Until now. Introducing VCX, a public ticker for private tech. Visit getvcx.com for more info. That's getvcx.com. Carefully consider the investment material before investing including objectives, risks, charges, and expenses. This and other information can be found in the Innovation Fund prospectus at getvcx.com. This is a paid sponsorship.